Omni Bio Pharmaceutical Inc

Omni Bio Pharmaceutical — Investor Presentation (September 2014)

27 slides from Omni Bio Pharmaceutical's investor presentation, Sep 11, 2014

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    OF niBio Corporate Presentation September, 2014

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward-looking statements. The forward-looking statements in this presentation are based on information available to us as of the date any such statements are made and w

  3. Slide 3: Omni Bio Value Proposition

    Slide 3: Omni Bio Value Proposition

    Omni Bio Value Proposition Emerging biopharmaceutical company with patented- protected, recombinant technology based on alpha-1 antitrypsin (AAT) Advancing to key risk-reducing milestones over next 6 months * OP riBio aaa

  4. Slide 4: Corporate Snapshot

    Slide 4: Corporate Snapshot

    Corporate Snapshot + Targeting immune-mediated inflammatory diseases with high unmet medical need Focused Opportunity + AAT-Fc: First-in-class recombinant technology similar to Enbrel® De-Risked + Leverages emerging science from studies of plasma-derived AAT (p-AAT) Technology Platform moe p-AAT cur

  5. Slide 5: Broad Array of High-Value Targets

    Slide 5: Broad Array of High-Value Targets

    Broad Array of High-Value Targets Therapeutic Options Market Potential (US/EU) Graft vs Host Disease ~$500M Type 1 Diabetes (Early Onset) >$1B Chronic Gout >$1B Supplementation Therapy >$500M Rheumatoid Arthritis >$1B Inflammatory Bowel Disease >$1B COPD >$1B Post-MI Heart Disease >$1B Initial Targe

  6. Slide 6: Targets Supported by Growing Evidence

    Slide 6: Targets Supported by Growing Evidence

    Targets Supported by Growing Evidence . . * p-AAT studied in diabetes, islet cell transplantation, GVHD, Extensive Animal gout, inflammatory bowel disease, myocardial infarction Model Data and more * AAT-Fe equally effective at 40-50x lower doses in models, of gouty arthritis, IBD and AMI + Type 1 d

  7. Slide 7: AAT-Fc Positioned for Commercial Success

    Slide 7: AAT-Fc Positioned for Commercial Success

    AAT-Fc Positioned for Commercial Success a + Extracted & purified from whole + Fe-fusion protein similar to Enbrel® blood eet + Safely used for >25 years, but: + Greatly expanded market potential: + Weekly, 1 to 2-hr I.V. infusions + 40-50x more potent; longer half-life + ~$100k / patient / year * P

  8. Slide 8: Strategic Options for AAT-Fc Development

    Slide 8: Strategic Options for AAT-Fc Development

    Strategic Options for AAT-Fc Development Develop Alone Co-Develop Out-License Through Phase 2a with Partner To Pharma Co. + 3-4 year outlook * 1-3 year outlook + Most likely from Phase iti . " . 1 onward + Additional funding of * Any time from cell line ~$15M required optimization onward + Leveraged

  9. Slide 9: AAT-Fc Development Timeline

    Slide 9: AAT-Fc Development Timeline

    AAT-Fc Development Timeline St CellLine Toxicology Complete Optimization T File IND vw 2014 2 2016 2017 2018 Emerging p-AAT Data Mfg Milestones AAT-Fc Clinical Studies : OP riBio aaa | tot ft

  10. Slide 10: Additional Investment Needed to Achieve Milestones

    Slide 10: Additional Investment Needed to Achieve Milestones

    Additional Investment Needed to Achieve C AAT-Fc Milestones* $5-6 M $2-3M $5-6M Now 2016 2017 Complete Preclinical Conduct 1 Human Conduct 1* Patient Development Trials Trial + Process/formultion! + Phase t cinicl trials + Phase 2a cinical trial to anaiyica development + na safety, pd & estes ‘Prat

  11. Slide 11: Value Creation Roadmap

    Slide 11: Value Creation Roadmap

    Value Creation Roadmap Cell Line * Complete AAT-Fe cell line optimization in 4Q 2014 to enable first imization/Mfg GMP manufacturing in 2015 Vv Partnered with Sigma Aldrich and Gallus BioPharmaceuticals Pre-IND Studies of * Publish ancillary animal pharmacology studies AAT-Fo * Conduct IND-enabling

  12. Slide 12: Patent Estate Summary

    Slide 12: Patent Estate Summary

    Patent Estate Summary * Issued for lead technology in US; pending in Europe/Canada AAT-Fc Patents * Filed globally for multiple IgG Fe constructs * Filed globally for “hinge-modified’ backup series p-AAT Use Patent * Diabetes (Type 1 and Type 2) * Graft vs Host Disease (GVHD) = Non-organ transplanta

  13. Slide 13: Highly-Experienced Executive Team

    Slide 13: Highly-Experienced Executive Team

    Highly-Experienced Executive Team CEO CFO cso cDo Bruce Schneider, PhD Jack Riccardi,MBA Charles Dinarello, MD_—_—Bruce Forrest, MD + Over 36 years drug + Seasoned large and + World recognized + Over 25 years experience development experience small company executive “father of cytokine in immunology

  14. Slide 14: Shareholder Information

    Slide 14: Shareholder Information

    Shareholder Information Stock Symbol OMBP.PK Closing Stock Price (9/3/14) $0.25 52-week Range $0.12-0.50 Shares Outstanding 38.8 million Fully Diluted Shares 76.8 million Market Capitalization (9/3/14) $9.3 million Cash on Hand (6/30/14)* $0.7 million “exclusive of additional $1 million loan facilit

  15. Slide 15: Corporate Summary

    Slide 15: Corporate Summary

    Corporate Summary First- lass Recombinant Technology (AAT-Fc) ¥ Improved potency with superior scalability ¥ Potential for patient-friendly, subcutaneous self-administration Y Significantly de-risked by p-AAT history & emerging data ¥ AAT fundamental mediator of anti-inflammatory and tissue protecti

  16. Slide 16: Representative Data Slides

    Slide 16: Representative Data Slides

    Representative Data Slides * OP riBio aaa

  17. Slide 17: AAT-Fc Pharmacokinetics

    Slide 17: AAT-Fc Pharmacokinetics

    AAT-Fc Pharmacokinetics N=5 —= pAAT(1omara) E AAT-Fe (10mgiRO) “= pAAT Comers) og eS aatFeenata) 2 AAT (ug/ml) Pre-beoding Injection —>- AAT-Fc Prolongs Plasma Concentrations at Lower Doses a OP riBio

  18. Slide 18: Science Supports AAT-Fc Development in Several Medically Important Indications

    Slide 18: Science Supports AAT-Fc Development in Several Medically Important Indications

    Science Supports AAT-Fc Development in Several Medically Important Indications Inflammation & Gout Diabetes + AAT-Fe showed dose-dependent reduction in joint inflammation and IL-1B levels in a mouse model of gouty arthritis + Potency greater than p-AAT and anakinra + AAT protects insulin-producing i

  19. Slide 19: AAT-Fc reduced joint inflammation and IL-1 levels in gout model

    Slide 19: AAT-Fc reduced joint inflammation and IL-1 levels in gout model

    Treatment with AAT-Fc reduced joint inflammation and IL-1 levels in mouse model of gouty arthritis _ 24 p<0.001 ; 0.001 Q 18 i a” = 3 os a “eo oS oe SF eo ro ro e & ms a rl “4 hours after chemical:induced inflammation ° OP riBio

  20. Slide 20: AAT-Fc highly effective in clearing granular infiltrates

    Slide 20: AAT-Fc highly effective in clearing granular infiltrates

    AAT-Fc highly effective in clearing granular infiltrates that cause inflammation in gout model Ivig 50ug AAT-Fc 50ug oe < Ps aoe “4 hours after chemical-induced inflammation ” OPniB i

  21. Slide 21: Reduction in joint swelling competitive with p-AAT and anakinra

    Slide 21: Reduction in joint swelling competitive with p-AAT and anakinra

    Reduction in joint swelling competitive with p-AAT and anakinra yet at much lower doses "oe ay eee 3 peor, . pa001 = gq a i 1 0: “ oe fe e ¥ é ¢ ee v “4 hours after chemicalinduced inflammation * OP riBio

  22. Slide 22: p-AAT Data

    Slide 22: p-AAT Data

    p-AAT Data p-AAT protects insulin-producing islet beta-cells in multiple animal models — Restores immune tolerance to insulin-producing beta cells in NOD mice (a model of recent-onset Type 1 diabetes) — Preserves islet cell function and normalizes glucose levels Potential clinical benefit also shown

  23. Slide 23: p-AAT Data

    Slide 23: p-AAT Data

    p-AAT Data p-AAT treatment preserves islet cell function in mouse model (essential for insulin production) 2 1 A Bo >, i! — Days after initial therapy fig.2_sletnstloy of sponarcous abet NOD mice a recent onset of ‘ease and tearm wih AAT 100 dal ose). NOD paces ae Keulmanda eta (2008) PNAS 105; 1624

  24. Slide 24: p-AAT Data

    Slide 24: p-AAT Data

    p-AAT Data 8-week dosing in patients suggests stabilization of C-peptide levels = 2.0 zZ = Pediatric 2 ~ > Adult £15 8 z Mean change from baseline: 2 1.0 Adult +0.013 (9-0.852), a + Pediatric: -0.191 (p=0.148) 20.5 : 20.0 r 7 : r 1 0 100 200 300 40 Study Day Nit’ immune Tolerance Network RETAIN stud

  25. Slide 25: p-AAT Data Graft vs Host Disease

    Slide 25: p-AAT Data Graft vs Host Disease

    p-AAT Data Graft vs Host Disease (GvHD) p-AAT reduces mortality from GvHD in mouse transplant model 400 Pro-inflammatory cytokines reduced — TNF-a, IL-1, and NF-kB, Phd z. ~e Matched Transplant (n=8) IL-10 increased 3 a ‘“& Mis-matched Transplant (n=9) 3 “ Mis-matched Transplant Ratio of anti-graft

  26. Slide 26: AAT-Fc/p-AAT Data Post-MI

    Slide 26: AAT-Fc/p-AAT Data Post-MI

    AAT-Fc/p-AAT Data Post | He: Anti-inflammatory and cardioprotective effects — Demonstrated in mouse models of myocardial infarction — Infarct size reduced & systolic function improved with both p-AAT and AAT-Fe Clinical trial of post-MI inflammatory response with p-AAT — Being studied in patients wi

  27. Slide 27: p-AAT reduces acute myocardial infarct size in mouse model

    Slide 27: p-AAT reduces acute myocardial infarct size in mouse model

    p-AAT reduces acute myocardial infarct size in mouse model AAT Infarct, ; v . " N=6 pergroup * P<0.05vssham ** P<0.05 vs Albumin Albumin Infarct Toto eta @011) IMI Cel Cadel $1}: 24451 % 2 _ OmniBio aaa

Source: SEC EDGAR · 8-K filed Sep 11, 2014

More decks from Omni Bio Pharmaceutical Inc